Praxis Precision Medicines, Inc. (PRAX)
NASDAQ: PRAX · Real-Time Price · USD
317.25
+19.51 (6.55%)
At close: Jan 16, 2026, 4:00 PM EST
313.00
-4.25 (-1.34%)
After-hours: Jan 16, 2026, 7:40 PM EST
PRAX Revenue
Praxis Precision Medicines had revenue of $7.46M in the twelve months ending September 30, 2025, up 364.98% year-over-year. In the year 2024, Praxis Precision Medicines had annual revenue of $8.55M with 249.53% growth.
Revenue (ttm)
$7.46M
Revenue Growth
+364.98%
P/S Ratio
1,179.17
Revenue / Employee
$64,336
Employees
116
Market Cap
8.80B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8.55M | 6.11M | 249.53% |
| Dec 31, 2023 | 2.45M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PRAX News
- 9 days ago - Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 10 days ago - Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments - GlobeNewsWire
- 12 days ago - Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering - GlobeNewsWire
- 12 days ago - Praxis Precision Medicines, Inc. Announces Proposed Public Offering - GlobeNewsWire
- 20 days ago - Praxis Precision Medicines To Rally More Than 213%? Here Are 8 Top Analyst Forecasts For Monday - Benzinga
- 20 days ago - Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor - GlobeNewsWire
- 5 weeks ago - Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 - GlobeNewsWire
- 5 weeks ago - Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy - GlobeNewsWire